| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-07-19 | Novasep (France) instrAction (Germany) |
chromatography processes for purification |
other |
See details |
| 2010-07-19 | Vivalis (France) Boehringer Ingelheim (Germany) |
EB66® cell line for production of two poultry vaccines |
licensing |
See details |
| 2010-07-16 | Galapagos (Belgium) University of Bristol (UK) |
new analgesic drug based on the protein galanin, small protein that has been shown to reduce neuropathic pain in a number of models of diseases, including diabetes. / Diabetic neuropathic pain |
R&D development |
See details |
| 2010-07-15 | Cytos Biotechnology (Switzerland) Singapore’s Agency for Science, Technology and Research (A*STAR) |
virus-like particle (VLP) vaccine / influenza |
R&D commercialization/ distribution development |
See details |
| 2010-07-15 | Lonza (Switzerland) Elusys Therapeutics (USA) |
Anthim® This humanized and deimmunized monoclonal antibody targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. / Anthrax |
manufacturing |
See details |
| 2010-07-13 | Human Genome Sciences (USA) Lonza (Switzerland) |
Benlysta® (belimumab - BLyS-specific inhibitor) It is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006. / stemic lupus erythematosus |
manufacturing |
See details |
| 2010-07-12 | OctoPlus (The Netherlands) The Medicines Company (USA) |
MDCO-216 (ApoA-I Milano/phospholipid complex). |
manufacturing development |
See details |
| 2010-07-12 | Galapagos (Belgium) NIH (USA) |
Molecular Libraries Small Molecule Repository (MLSMR) | other |
See details |
| 2010-07-08 | Eurofins MWG Operon (Germany) Genomatix (Germany) |
Sequencing solutions |
other |
See details |
| 2010-07-07 | Proximagen (UK) National Institute of Neurological Disorders and Stroke (NINDS – USA) |
Naluzotan (5-HT1a receptor agonist) Proximagen is currently undertaking studies in models of Parkinson’s disease to determine the utility of naluzotan in alleviating dyskinesia induced by dopaminergic therapy. / epilepsy |
other |
See details |
| 2010-07-07 | TcLand Expression (France) Inserm Transfert (France - technology transfer subsidiary of the French National Institute for Health and Medical Research - Inserm) |
Patents covering gene expression signatures which can predict responsiveness to rheumatoid arthritis. The first patent application WO2007IB02373, has been filed on May 15, 2007 and is entitled “A method for predicting responsiveness to TNF alpha blocking agents” (first-listed inventor: Jean-Philippe Salier). The second one, EP 083052522, has been filed on June 12, 2008 and is entitled “A method for predicting the response to a treatment with anakinra” (first-listed inventor: Thierry Lequerré). / rheumatoid arthritis |
licensing |
See details |
| 2010-07-07 | Aquapharm Biodiscovery (UK) Albany Molecular Research (USA) |
Composé drug-like compounds with anti-microbial and anti-inflammatory activity / inflammatory diseases, infectious diseases | R&D |
See details |
| 2010-07-06 | Pharming (the Netherlands) Sanofi Chimie (France) |
Ruconest® (Rhucin® - recombinant human complement protein C1 inhibitor (rhC1INH), produced in transgenic rabbit milk) / angioedema attacks | manufacturing |
See details |
| 2010-07-06 | Swedish Orphan Biovitrum (Sweden) Dongbao (China) |
commercialization/ distribution |
See details | |
| 2010-07-05 | MRC Technology (UK) AstraZeneca (UK) |
compound libraries / serious diseases including the area of cancer, cardiovascular diseases, neuroscience, and infection | R&D |
See details |
